Biotech · Private company · Cambridge, MA, US
Mersana Therapeutics, Inc.
SEC CIK 0001442836
Track this companyFree. Adds Mersana Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- Upifitimab rilsodotinPhase 3 · High Grade Serous Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- upifitamab rilsodotinPhase 2 · Platinum Resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · Platinum-sensitive Ovarian Cancer (UPGRADE-A)ClinicalTrials.gov · fetched Nov 12, 2026
- XMT-1522Phase 1 · Advanced Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- XMT-1536 (Upifitamab Rilsodotin)Phase 1 · Platinum-sensitive Ovarian Cancer (UPGRADE-A)ClinicalTrials.gov · fetched Nov 12, 2026
- XMT-1592Phase 1 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)PHASE3 · TERMINATED · started Jun 23, 2022ClinicalTrials.gov NCT05329545 · fetched Nov 12, 2026
- Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian CancerPHASE1 · TERMINATED · started Jun 11, 2021ClinicalTrials.gov NCT04907968 · fetched Nov 12, 2026
- First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2bPHASE1 · TERMINATED · started May 11, 2020ClinicalTrials.gov NCT04396340 · fetched Nov 12, 2026
- First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2bPHASE1 · COMPLETED · started Jul 30, 2019ClinicalTrials.gov NCT06517485 · fetched Nov 12, 2026
- First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2bPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 12, 2017ClinicalTrials.gov NCT03319628 · fetched Nov 12, 2026
- First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2bPHASE1 · COMPLETED · started Dec 12, 2017ClinicalTrials.gov NCT06517433 · fetched Nov 12, 2026
- Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2PHASE1 · COMPLETED · started Nov 21, 2016ClinicalTrials.gov NCT02952729 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Jan 6, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 5, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 13, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 24, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 3, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 13, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 2, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2025 · fetched Nov 12, 2026